Mesoblast (ASX:MSB) has licensed its lead drug candidate to Novartis (NYSE:NVS) in a deal that could be worth as much … Read More
The post Mesoblast in potential $1.7bn partnership with Novartis to develop remestemcel-L appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.